Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria.

@article{Iwamoto2017EfficacyAS,
  title={Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria.},
  author={Kazumasa Iwamoto and Hae Sim Park and Atsuyuki Igarashi and Young Min Ye and Tae-Bum Kim and Akiko Yagami and Jooyoung Roh and Jae-Hyun Lee and Yuko Chinuki and Sang Woong Youn and Soo-Keol Lee and Naoko Inomata and Jeong-Hee Choi and Atsushi Fukunaga and Junyi Wang and Soichiro Matsushima and Steve Greenberg and Sam Khalil},
  journal={Journal of dermatological science},
  year={2017},
  volume={87 1},
  pages={70-78}
}
BACKGROUND Many patients with chronic spontaneous/idiopathic urticaria (CSU/CIU) do not respond adequately to treatment with non-sedating H1 antihistamines (H1AH). There are limited studies on use of omalizumab as add-on therapy for treatment of CSU in an Asian population. OBJECTIVE The POLARIS study (NCT02329223), representing the first randomized, double-blind, placebo-controlled phase III trial of omalizumab for CSU in an Eastern Asian population, evaluated efficacy and safety of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…